therapy

The Cureus Journal of Medical ScienceSodium-Glucose Cotransporter-2 (SGLT2) Inhibitors and Risk of Heart Failure Hospitalization in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled TrialsSodium-glucose cotransporter-2 (SGLT2) inhibitors have emerged as a transformative therapy in type 2 diabetes mellitus (T2DM),….18 hours ago

The Cureus Journal of Medical ScienceSodium-Glucose Cotransporter-2 (SGLT2) Inhibitors and Risk of Heart Failure Hospitalization in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled TrialsSodium-glucose cotransporter-2 (SGLT2)…

Read more

The Cureus Journal of Medical ScienceCardiometabolic Benefits and Risks of Sodium-Glucose Co-Transporter-2 (SGLT-2) Inhibitor and Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Combination Therapy in Type 2 Diabetes: A Systematic ReviewType 2 diabetes (T2DM) management increasingly focuses on cardiometabolic protection. Sodium-glucose co-transporter-2 inhibitors (SGLT2is)….1 day ago

The Cureus Journal of Medical ScienceCardiometabolic Benefits and Risks of Sodium-Glucose Co-Transporter-2 (SGLT-2) Inhibitor and Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Combination Therapy in Type 2 Diabetes: A Systematic ReviewType 2…

Read more

Savvy Update, 7/7/25: 3D printed islet transplantation, next-generation glucagon analog/therapy funded abvance therapy, ax-4 space mission research to prevent hypoS, conducting research on glucose metabolism and microgravity, assistive systems, FDA dialogue system implementation

This week's issue of The Savvy Diabetic: 3D printed islet transplantation Abvance therapy funded for next-generation glucagon analogs/therapies Glucotrack's CBGM Implant Technology The AX-4 Space Mission Study Glucose Metabolism and…

Read more